GSEP
ALNY icon

Golden State Equity Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Golden State Equity Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.1K Sell
100
-94
-48% -$28.4K 0.08% 138
2026
Q1 		$64.2K Buy
+194
New +$66K ﹤0.01% 834
2024
Q4 		– Sell
-23
Closed -$6.33K – 453
2024
Q3 		$6.33K Buy
+23
New +$5.99K ﹤0.01% 741

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Golden State Equity Partners's ALNY Position: Q2 2026 in Review

Golden State Equity Partners reduced its Alnylam Pharmaceuticals (ALNY) stake by 48% in Q2 2026, selling an estimated $28.4K and leaving 100 shares worth $30.1K. The position accounts for 0.08% of the portfolio, ranked #138.

Golden State Equity Partners first reported a position in ALNY in Q3 2024 and has held it in 3 quarters since. The position peaked at $64.2K in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Golden State Equity Partners held 100 shares of Alnylam Pharmaceuticals worth $30.1K as of Q2 2026.
  • Golden State Equity Partners sold 94 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $28.4K.
  • Alnylam Pharmaceuticals made up 0.08% of Golden State Equity Partners's portfolio in Q2 2026, its #138 holding.
  • Golden State Equity Partners first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • Golden State Equity Partners's Alnylam Pharmaceuticals position peaked at $64.2K in Q1 2026.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.